Last reviewed · How we verify

NCT07215884

Dopamine and Sensorimotor Function in Stuttering

Recruiting now Phase 1 Last updated 14 October 2025
What this trial tests

Phase 1 trial testing Aripiprazole 10 MG in Stuttering, Adult in 40 participants. Currently enrolling.

Timeline
30 September 2025
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorUniversity of California, San Francisco
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposebasic science
Enrollment40
Start date30 September 2025
Primary completion30 June 2026
Estimated completion30 June 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Francisco

Who can join

Adults 18 to 65, any sex, with Stuttering, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency. This study aims to understand sensorimotor pathways of stuttering and possible interventions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Aripiprazole 10 MG

Trials testing the same drug.

Other recruiting trials for Stuttering, Adult

Currently open trials in the same condition.

Other University of California, San Francisco trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07215884.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing